Akebia Therapeutics Inc.
AKBA
Market Cap$958.62M
Close$
$-2.33
163.8% downside
Current Fair Value
163.8% downsideOvervalued by 163.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $958.62 Million |
|---|---|
| Enterprise Value | $900.64 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.33 |
| Beta | 0.84 |
| Outstanding Shares | 235,497,720 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -18.97 |
|---|---|
| PEG | 14.16 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.92 |
| Enterprise Value to EBIT | -38.09 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 2.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler